Thus, the direct targeting of Ang-(1-7) may provide an alternate approach to improve the cardiometabolic function in obesity hypertension while avoiding the off-target side effects seen with current RAS-blocking therapies. This evidence concerns the gene ANG and hypertensive disorder.